Sensex, Midcap higher; Reliance,Tata Motors
ICICI lead Equity benchmarks as well as broader markets continued to hold early gains with the Sensex rising over 100 points, led by oil, banks and auto stocks.Buzzing: Share price of Ajanta Pharma gained 2.5 percent intraday on USFDA approval for Duloxetine hydrochloride delayed release capsules
Duloxetine is a bioequivalent generic version of Cymbalta delayed release capsules and part of an ever growing portfolio of products that the company has developed for the US market. The company will launch the product shortly in 3 strengths, 20 mg, 30 mg and 60 mg strengths capsules. The company has 32 abbreviated new drug application (ANDA) of which it has 17 final ANDA approvals, 2 tentative approvals and 13 ANDAs under review with USFDA.
Buy, sell, hold: 21 large & midcap stocks to boost portfolio Check Equity benchmarks as well as broader markets continued to hold early gains with the Sensex rising over 100 points, led by oil, banks and auto stocks. The 30-share BSE Sensex was up 126.06 points at 26852.61 and the 50-share
NSE Nifty rose 39.40 points to 8275.45 while the BSE Midcap and Smallcap indices gained half a percent each. The market breadth was positive as about two shares advanced for every share falling on the exchange. Surendra Goyal of Citi says the market is likely to be rangebound till some clarity emerges. He maintains September 2017 target of 30,000 on the Sensex. Reliance Industries, Tata Motors, ICICI Bank, ONGC, Adani Ports and Tata Steel gained more than 1 percent whereas Axis Bank, TCS, Sun Pharma and Bharti Airtel were moderately lower
Read more for Best Stock Tips-http://www.aceinvestmentadvisory.com
ICICI lead Equity benchmarks as well as broader markets continued to hold early gains with the Sensex rising over 100 points, led by oil, banks and auto stocks.Buzzing: Share price of Ajanta Pharma gained 2.5 percent intraday on USFDA approval for Duloxetine hydrochloride delayed release capsules
Duloxetine is a bioequivalent generic version of Cymbalta delayed release capsules and part of an ever growing portfolio of products that the company has developed for the US market. The company will launch the product shortly in 3 strengths, 20 mg, 30 mg and 60 mg strengths capsules. The company has 32 abbreviated new drug application (ANDA) of which it has 17 final ANDA approvals, 2 tentative approvals and 13 ANDAs under review with USFDA.
Buy, sell, hold: 21 large & midcap stocks to boost portfolio Check Equity benchmarks as well as broader markets continued to hold early gains with the Sensex rising over 100 points, led by oil, banks and auto stocks. The 30-share BSE Sensex was up 126.06 points at 26852.61 and the 50-share
NSE Nifty rose 39.40 points to 8275.45 while the BSE Midcap and Smallcap indices gained half a percent each. The market breadth was positive as about two shares advanced for every share falling on the exchange. Surendra Goyal of Citi says the market is likely to be rangebound till some clarity emerges. He maintains September 2017 target of 30,000 on the Sensex. Reliance Industries, Tata Motors, ICICI Bank, ONGC, Adani Ports and Tata Steel gained more than 1 percent whereas Axis Bank, TCS, Sun Pharma and Bharti Airtel were moderately lower
Read more for Best Stock Tips-http://www.aceinvestmentadvisory.com
No comments:
Post a Comment